ADALTA LIMITED - Charts / Financials

0.00%

0.3¢

Market Cap $8.927M

Healthcare Biotechnology

AdAlta Limited is an Australia-based drug discovery and development company. The Company... AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

REFRESH

Last update - 07.00am 31/07/2026 (20 minute delay)

Day
Open	0.3¢		Day High	0.3¢		Day Low	0.3¢
Daily Volume	263000

Bids				Sellers
Number	Price	Volume		Number	Price	Volume
0	0.3¢	22402218		0	0.4¢	14374438

Directors & Senior Management

Dr. Andrew Peter O'Brien	Head of Corporate Development
Mr. Angus Tester	Senior Director of Operations
Dr. Brian Richardson	Scientific Advisor
Mr. Cameron Peter Jones	Company Secretary
Mr. Fadi Diab	Non-Executive Director
Ms. Janette Dixon	Head of Business Development
Mr. John Westwick	Scientific Advisor
Dr. Kevin Patrick Lynch	Consultant Chief Medical Officer of Oncology
Prof. Michael Foley	Founding Chief Scientist
Ms. Michelle Elizabeth Burke	Non-Executive Director
Dr. Paul Donald Richard MacLeman	Non-Executive Chairman
Dr. Steve Felstead	Scientific Advisor
Dr. Timothy Charles Oldham	CEO, MD & Director

Data source: ADVFN

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 0.3¢		Change 0.000(0.00%)		Mkt cap ! $8.927M

Open	High	Low	Volume
0.3¢	0.3¢	0.3¢	263K

Buyers (Bids)

Vol.	Price($)
22402218	0.3¢

Sellers (Offers)

Price($)	Vol.
0.4¢	14374438

Last trade - 07.00am 31/07/2026 (20 minute delay)

1AD (ASX) Chart